Stardom University

Stardom Scientific Journal of Natural and Engineering Sciences

- Stardom Scientific Journal of Natural and Engineering Sciences -
Peer Reviewed Scientific Journal published twice
a year by Stardom University
1st issue- 4th Volume 2026
ISSN 3756-2980



بِسْمِ اللَّهِ الرَّحْمَٰنِ الرَّحِيمِ

هيئة تحرير مجلة ستاردوم العلمية للعلوم "الطبيعية والهندسية"

Early Detection and Intervention for Growth Hormone Disorders in Children:

A Clinical and Theoretical Framework for Reducing Healthcare Costs and Enhancing Social Development in Egypt.

Hend R. Tawfik
Department of Basic and Applied Science, Arab Academy for Science, Technology and Maritime Transport (AASTMT), Egypt.
Productivity and Quality Institute, Arab Academy for Science, Technology and Maritime Transport (AASTMT), Egypt.
Email: hendrashaddeeb@gmail.com

Ahmed F. Elnokrashy
Center for Informatics Science (CIS), School of Information Technology and Computer Science, Nile University, 26th of July Corridor, Sheikh Zayed City, Giza, 12588, Egypt.
Department of Electrical Engineering, Benha University, 13511, Benha, Egypt.
Emails: ANokrashy@nu.edu.eg; Ahmed.elnokrashy@bhit.bu.edu.eg

Samir Y. Marzouk
Department of Basic and Applied Science, Arab Academy for Science, Technology and Maritime Transport (AASTMT), Egypt.
Productivity and Quality Institute, Arab Academy for Science, Technology and Maritime Transport (AASTMT), Egypt.
Email: Samir_marzouk2001@yahoo.com

Mai S. Mabrouk*
Center for Informatics Science (CIS), School of Information Technology and Computer Science, Nile University, 26th of July Corridor, Sheikh Zayed City, Giza, 12588, Egypt.
Email: masaid@nu.edu.eg

*Corresponding authors: Hend R. Tawfik (hendrashaddeeb@gmail.com), Mai S. Mabrouk (masaid@nu.edu.eg)

Abstract

Although early diagnosis is underutilized in many care settings, children with growth hormone (GH) disorders have developmental delays, obesity, and high costs that are rising globally. This study examines the costs and outcomes of the innovative approaches such as the GH/BMI Screening Interventions on the health and social development of children In LMICs. In the cross-sectional study which was conducted in a multi-center setting, a sample of 1000 children aged between 1 and 10 from multiple countries were enrolled. The collection of the sample, preprocessing, designing of the experiment, and all the statical analyses were done in a systematic manner. The Pre-Development Screening Questionnaire (KPSP) was administered at the beginning of the intervention and periodical intervals and intervals of 3 months to measure mass index, plasma development hormone, and plasma thyroid-stimulating hormone (TSH) levels and developmental milestones attained, in the framework of the 1-year period on the environmental change, muscle activity via exercises, and the guidelines on food to be consumed. The preprocessing of the data included quality control, normalization, and imputation of missing data. Statistical analyses were performed using SPSS v26 and included descriptive statistics, paired t-test, ANOVA, multiple linear regression, and Pearson correlation. The results revealed that there were statistically significant modulations in each of the measured parameters with GH level increased 311% (i.e., from 1.59 ± 0.83 to 6.54 ± 0.87 ng/mL), TSH to be raised up to 5.04 ± 0.32 μIU/ml which could represent higher thyroid function activities, and BMI decreased by about twenty percent (from23.94±0.56to19.23±0.43 kg/m²;all p<:0001). The developmental score improved significantly ($R^2 = 0.65$), with BMI decrease and GH increase representing the major most powerful predicting factors at outcome. The cost-benefit analysis modelled significant reductions in health care costs with application to other

pediatric populations. Early GH and BMI screening, and application of non-pharmacological measures have strong potential to improve health and save healthcare costs as well as promote social development confirming on separately international pediatric healthcare systems.

Keywords: Growth hormone, BMI, early detection, pediatric health, cost reduction, social development, screening framework

Abbreviations

GH – Growth Hormone

GHD – Growth Hormone Deficiency

BMI – Body Mass Index

TSH – Thyroid Stimulating Hormone

KPSP – Kindergarten and Primary School Screening Psychological Test

LMICs – Low- and Middle-Income Countries

SDGs – Sustainable Development Goals

1. Introduction

Due to intricate interactions between physiological, psychological, and environmental factors, schoolchildren's chronic fatigue, poor academic performance, and declining athletic ability constitute a serious global public health crisis (Richter et al., 2017; World Health Organization, 2016). These problems, which include endocrine disorders, especially growth hormone deficiency (GHD), stress, sleep disorders, physical inactivity, and nutritional deficiencies, impact 25–30% of children in low- and middle-income countries (Gollins et al., 2025; Osei Bonsu and Addo, 2022).

GHD profoundly affects academic and athletic performance due to growth retardation, short stature, chronic fatigue, and diminished physical and cognitive abilities caused by insufficient growth hormone secretion from the anterior pituitary (Wu and Luo, 2025; Yuan et al., 2022). The disorder, which frequently advances silently and exacerbates developmental delays with long-term health complications, is still underdiagnosed because its symptoms can be mistaken for those of malnutrition or behavioral problems (Ibba and Loche, 2022; Salah et al., 2013).

Internationally, GHD is estimated to be present in 10-15% children with short stature; however, the lack of protocol-driven screening has led to late diagnoses as further treatments are less effective beyond age 5 years (Brettell et al., 2023; Elashmawy et al., 2019). The early detection of GH deficiency through periodic screening provides for the commencement of early treatment that should result in normal growth, energy and cognition with an improved quality-of-life (Jones et al., 2023; Malone et al., 2022) and a decrease in future healthcare costs.

Failure to address GH deficiency (GHD) unrepaired to imposes a tremendous impact on the family and the economy; the health care system will still have the expensive therapies of hormone medicines and even surgery to deal with (Moldovan et al., 2022; Cowie et al., 2020). Also screening, to save on the cost of complications, is an efficient way to handle the long-term expenses of health care, saving 20 to 30% (Bamford et al., 2019; Colizzi et al., 2020).

The United Nations Sustainable Development Goals (SDGs) advocate for improvement in this sector and human health at the same time, with particular focus on equity in health and human development (Hoang et al., 2024; Solomon et al., 2021). GHD is complex and thus needs a coordinated action program linking health care, education, and local communities (Schiariti et al., 2021; Mustafa et al., 2024). Over the last couple of years, this is an area of service that has been proposed to shift

under the pediatric department specialized in the guidance of systematic early intervention and detection (Weitzman et al., 2025; Health Service Executive, 2018).

The potential integration of machine learning in risk prediction alongside point of care Insulin like Growth Factor Assay stand to revolutionize health systems by cost effective screening leverages (Read and Meath, 2025; Ministry for Health Malta, 2022). International pilot programs suggest that routine screening for GH will enhance health outcomes, and results achieved by 20 to 25% cost savings (Bruner et al, 2020; Children's Safety Network, 2020).

Traditionally, the frameworks used to improve the sustainability of pediatric health have come from various avenues. Malone et al. (2022) described a framework for sustaining the implementation of innovations in pediatric hospitals that was based on the intersection of quality improvement and implementation science with a focus on leadership and institutional capacity. The findings have limited generalizability to the community or school setting particularly in low- and middle-income countries (LMICs) given it was conducted in a hospital setting. In a successful project to integrate oral health services into school-based health centers, Lowe, Barzel, and Holt (2016) developed a theoretical framework to prepare and implement oral health services in these school-based sites. However, this framework is for a disease, and not adapted on a broader endocrine or metabolic screening of GH or BMI. Likewise, the national strategy for alcohol and other drugs put forth by the Ministry for Health (Malta, 2022) emphasized prevention and the need for system-level planning, but is not applicable to low resource contexts without assessment of cost-efficiency. Moldovan et al. Unfortunately, although their San-Q framework linking sustainability with human rights and health services quality assessment is very innovative and originally, it is even theoretical and we might say more sowordless in the context of community-based pediatric screening (2022).

The current research synthesizes and builds upon these viewpoints by creating a pragmatic, empirically supported, and contextually flexible model for early growth monitoring and body mass index screening in low- and middle-income countries. It translates the conceptual groundwork laid by Jones et al. (2023)—who only conceptually discussed the Theory of Change in abstract terms—into an actual intervention connecting early health detection to outcomes that can be measured in terms health and costs. In addition, contrary to Malone's hospital-centric model, this work creates a community- and school-level referral pathway, integrating screening, primary care, and laboratory diagnostics to streamline and cut costs and time. The model tackles the issues of equity and sustainability, as pronounced by the Maltese national strategy and Moldovan's San-Q approach, addressing access and alignment

with policy. Thus, this study contributes to the field by integrating the clinical, developmental, and economic aspects to lay down a fully scalable model that closes the gap between theory and practice in public health.

Despite the growing literature on pediatric endocrine disorders, most previous studies have focused primarily on pharmacological treatment of growth hormone deficiency within hospital settings. Limited attention has been given to integrated community-based screening strategies that combine hormonal monitoring, anthropometric assessment, and developmental evaluation.

The novelty of the present study lies in proposing a hybrid preventive–developmental framework that integrates GH and BMI screening with lifestyle-based interventions and cost–benefit evaluation. Unlike previous research, this study simultaneously examines clinical, developmental, and economic outcomes within a scalable model suitable for low- and middle-income countries. This integrated perspective provides new evidence for early detection strategies that can improve child development while reducing long-term healthcare costs.

Therefore, the aim of this study is to evaluate the effectiveness of an integrated GH/BMI screening and intervention framework in improving hormonal balance, developmental outcomes, and healthcare cost efficiency among children in low- and middle-income settings.

3. Methodology

The study followed a structured methodological framework to ensure reproducibility and transparency. All procedures including participant recruitment, anthropometric measurements, laboratory analyses, developmental assessments, and statistical analyses were conducted according to standardized clinical protocols. Ethical approval was obtained from the relevant institutional review board, and informed consent was obtained from parents or guardians before participation.

3.1 Experimental Setup

Cross-sectional, Multi-Centre Study in Children using an Experimental Design Screening large vs small size. These children from the study sample relied on the results obtained from the Harvard BMI chart, then underwent growth hormone (GH) therapy. Effectiveness focused on detecting growth disturbances in different children. The considered-method stemmed from the corporate logical structure of

"meditate, arrange, organize the base information" and "complete numerous assorted statistical approaches to reach a conclusion."

Phase 1-Data Collection:

Along with the protocol approved by the ethical committee, this multicenter study involves the recruitment of a sample comprising 1000 children with parental informed consent which is to be collected from schools as well as community health centers and hospitals.

Phase 2- Clinical and laboratory evaluation (GH, TSH and Body mass index), KPSP questionnaire Developmental assessment.

Phase 3- Pre-processing: Data as a whole need to be scrutinized for any discrepancies in order to be considered. Such discrepancies included but are not limited to poorly constructed datasets, missing and/or outliers and values within a dataset that are in a different order of magnitude. Data needs to be standardized for evaluation within the study and across multiple sites and time periods.

Phase 4- Statistical Analysis: Multiple paired t-tests were run to establish the means to compute the intervention effects on GH and TSH measures along with BMI levels, and ANOVA were performed on the development outcomes, along with multi-regression and correlate interaction with development outcome analyses.

Intervention Programme: This non-pharmacological approach includes 1:1 nutrition counseling, targeted physical activity, and enhancement of the food and play environment.

Outcome Diagnosis: This includes the health, development, economic outcome variables as well as the policy analysis and estimated savings on health care expenditures.

3.2 Procedures for Data Collection

The sampling distribution included >1 to >20 sites across countries with pediatric clinics, schools, and community health centers, dispersed in both urban and rural areas to gain variability in geography and socioeconomics.

Each age group of participants was assigned equally for a longitudinal study. As part of this protocol on primary school children, to keep some participants for the age

group that was to be non-targeted, we collected a longitudinal study on “1,000 children” between 1 to 10 years of age. This was done by having a targeted quota of 100 children for every age increment.

In every stage of the study, children who had crossed the age of 10 and were dealt with in terms of a cross sectional in 10 years and were waited for in order to check whether growth had started. Participation was gained from diverse health services across social divisions remotely based on socioeconomic status by area of residence.

Parents were explained the objectives of the study along with criteria based on age and growth, developmentally delayed children who pass through structured interviews, with the criteria of needing parental consent and follow through stages of increase. They were all gained from children who are growth deficient. Any youngsters bore children with chronic diseases directly associated to growth such as a disease of the metabolism, diagnosed with GH and who have up until that particular stage were treated.

Data collection was completed in 2 stages. The children who were boarded for the interventions were crossed with children who had the age range targeted during works of cross section. The cross section was done in the initial stage 100% covering all children who were developmentally delayed.

HCYLSC instituted defined guidelines for on-site anthropometric measurements, laboratory and developmental assessments screening lass all the stages to ensure obtained data could be compared across different locations.

Anthropometric data were collected using BODY CODER-certified tools—precision platform scales and calibrated stadiometers—within a defined cylinder protocol. For each participant, raw measurements were taken, and computed body mass indices were documented according to developmental and clinical strata. These were accompanied by primary evaluation and customized tools focusing on perinatal history, neonatal feeding practices, growth milestones during the evaluation period, and family history of select diseases to identify probable risks and confounding factors. These instruments were also focused on the developmental stage to ensure a complete assessment during the evaluation period.

All experiments observed the specified standardized protocols, which were conducted in the uninterrupted morning fasted state, with specimens collected via venipuncture by trained personnel. Samples were transported to accredited laboratory facilities where the analysts observed internal quality control standards prior to the analyses. Investigative components included a complete blood count, a

comprehensive panel assessing renal and hepatic function, and selective stool and urine tests designed to rule out systemic disorders that might affect growth in the body. Endocrine variables were assessed via basal SCISSORS immunoassays measuring intermittent growth hormone and basal plasma thyroid-stimulating hormone; the analytes were later assessed by dual immunoradiometric assays on the hormonal species directly related to statural growth.

Children were developed screened through utilization of the KPSP (Kindergarten and Primary School Screening Psychological Test), a developmental assessment of mastering motor skills, cognition/ language, and social skills or reaction at the age of 4 years.

Assessments were carried out on a scheduled basis (3, 6, 12, 24, 36, 48, 72 months) on children with developmental delay who required additional services in early intervention.

3.3 Data Preprocessing

As a preliminary step to any statistical analysis, automated quality control techniques, including the imputation of missing values and systematic verification, were employed to guarantee quality, accuracy, and integrity of the dataset. Clinical data were for instance consolidated, and disparate datasets of different origins were for instance cross-matched to ‘anchoring’ points, reverting back to the original dataset to generate logging and checking ‘information’ streams.

A negative or positive ‘outlier’ for developmental assessment scores, associated anthropometric measurements and laboratory outputs cross-validated against defined normative ranges, and ‘outlier’ detection techniques were, in this instance, ‘computing’ the z-score and checking the interquartile range of values for the associated cited z-score data.

Normative data and standards reflecting age and sex were for instance employed to assess and evaluate the respective laboratory measurements and anthropometric indices to derive subsequent standardized scores. Such unchecked values for statistical analysis were late to systematically derive, owing to the bias of the missing data structure and negative biasing.

3.4 Intervention Protocol

The one-year intervention aimed to multiple growth-restricting factors including over and under-nutrition and environmental constraints to healthy development. The dietary counseling comprised of age-appropriate diet plans prepared by registered pediatric dietitians based on the dietary deficiencies and the patient's age or trends for growth promoting diets.

Physical activity interventions were age-appropriate and aimed at lowering BMI while sustaining healthy growth and development. Strategies were categorized into i) supervised exercise within the trial ii) tailored advice for locally practiced physical activity.
To enhance public health, school and community partners improved access to safe play areas, healthy food, and clean drinking water. Parent workshops incorporated teachings on child nutrition, growth monitoring, health education, and culturally sensitive stigma reduction awareness.

3.5 Statistical Analysis Framework

All statistical analyses were conducted using IBM SPSS Statistics version 26. The analytical procedures included descriptive statistics, paired sample t-tests, ANOVA, Pearson correlation analysis, and multiple linear regression modeling. The statistical workflow and parameter settings are available upon request to ensure reproducibility of the results.

In SPSS version 26, diverse statistical approaches were used to analyze the effectiveness of the intervention and the relationships among the variables investigated to achieve the research objectives. The distributions of the GH, TSH, and BMI values were assessed before and after the intervention by calculating descriptive statistics, including mean, standard deviation, and 95% confidence interval.

Significant pre–post hormonal and anthropometric parameters differences were inferentially determined through paired t-tests. One-way ANOVA was conducted for grouped demographic variables such as age and socioeconomic status, and Tukey HSD test was performed when differences were statistically significant. To elucidate the relative contribution of GH, TSH, and BMI to developmental progress, pre-developmental KPSP scores were subjected to multivariate linear regression to assess the contribution of GH, TSH and BMI as independent predictors of the pre-developmental KPSP scores.

Primary outcomes included KPSP scores pre- and post-intervention, along with measurements of GH, TSH, and BMI. Age, gender, place of residence, and socioeconomic status were included as covariates to identify possible effect modifiers regarding response to treatment.

A cost–benefit analysis determined the net present value of early interventions within the benefit–cost ratio framework to estimate the healthcare return on investment. A sensitivity analysis was also conducted to assess the model's robustness at the base, optimistic, and pessimistic levels to reduce methodological bias. This helped ensure the clinical and cost effectiveness of the interventions was not overstated.

This framework provides a statistically validated structure upon which the clinical effectiveness and the economic viability of the program can be analyzed, guaranteeing that the conclusions reached are both dependable and applicable to other systems of pediatric health.



Figure 1. Study Framework for the Early Detection and Intervention of Growth Hormone Disorders in Children

4. Results and Discussion

The paired sample analysis provided evidence of stable and significant enhancement across all parameters evaluated. Data in table 1 shows that growth hormone (GH) levels increased by an average of 4.95 ng/, thyroid-stimulating hormone (TSH) levels increased by 2.10 µIU/mL, and the body mass index (BMI) dropped by 4.71 kg/m². These large effect sizes validate that the changes that occurred and the improvements that were realized were both physiologically and statistically meaningful, and were not random changes.

The p-values (< 0.001) are significant in all variables which show the implemented lifestyle-based program has a good causal effect. In addition, multiple linear regression model ($R^2 = 0.65$) showed that GH and BMI were the most significant predictors of developmental progress, together accounting for 65 % of the variance in developmental results.

After the intervention, the mean TSH concentration was 5.04 ± 0.32 μIU/mL and the variability decreased significantly (SD from 1.56 to 0.32) indicating increased endocrine homeostasis. These yields, higher than those reported by Brettell et al. The analysis by experiencing data up to October 2023 principally pertained to GH reaction with just pa made reference to thyroid interaction (23), observing that our also request relaxation, multi-parameter point of view is better at catching broad endocrine normalization.

Coinciding with this, BMI decreased to 19.23 ± 0.43 kg/m² corresponding to an average reduction of 20% and change in classification from overweight to near-healthy. The low post-intervention R^2 (0.24) implies that the improvement happened at all subgroups level (instead of the best/worst clusters), supporting the relevance and the scalability of the intervention results.

Table 1: Results of Paired T-Tests Before and After Intervention

Variable	Mean Difference	t-value	df	Sig. (2-tailed)	Effect Size (Cohen's d)
Growth Hormone (ng/mL)	4.95	58.76	999	<0.001	5.89
TSH (μIU/mL)	2.10	17.85	999	<0.001	2.12
BMI (kg/m²)	-4.71	-95.67	999	<0.001	-9.55

We performed correlation analyses that strongly supported the hypothesis that maximization of GH secretion improves cognitive and motor development. As shown in Table 2, there was a significant positive correlation between GH gain and developmental score gain ($r = 0.73$, $p < 0.001$) — Higher GH were associated with greater development consistently across the developmental range. Similarly, reduction of BMI and GH increase was positively associated ($r = 0.68$, $p < 0.001$) and TSH change was moderately positively correlated with the development score ($r = 0.45$, $p < 0.001$). In contrast, there was a moderate negative correlation with age

and treatment outcome ($r = -0.32$, $p < 0.001$), indicating that younger children were far more positive responders to the intervention than older children.

Such results support the previous findings based on Jones et al. (2023) who expressed the value of early intervention but whose work does not test its impacts on the course of development. The current program was successful because it was comprehensive and targets environmental, nutritional, and physical-activity factors together via a multi-modal intervention. This global approach activated hormone balance through GH stimulation from exercise and personalized nutritional guidance based on deficiencies.

In addition, the combination of organized active play and better nutrition addressed important social determinants of health that often limit child growth in underprivileged communities. Schiariti et al. also referred to similar multidimensional strategies. (2021) and Hoang et al. (2024) also emphasized the need for vertically-integrated school-based interventions that span the school, family, and health system to facilitate best growth and development.

Table 2: Variable Pearson Correlations

Variable Pairs	Correlation (r)	Significance	Interpretation
GH Improvement × KPSP Scores	0.73	p<0.001	Strong Positive
BMI Reduction × GH Increase	0.68	p<0.001	Strong Positive
TSH Change × Developmental Scores	0.45	p<0.001	Moderate Positive
Age × Treatment Response	-0.32	p<0.001	Moderate Negative

The multiple linear regression analysis (table 3) revealed growth hormone change, BMI change, and TSH change as significant predictors of developmental achievement (KPSP scores). The greatest standardized coefficient for GH change accounted for roughly 42 % of variance in the entire model. BMI change was

negatively associated, which meant that the higher the developmental outcome, the more BMI was reduced, and TSH change 8. It is highly predictive ($R^2 = 0.65$; $F = 245.6$; $p < 0.001$), accounting for 65 % of the variance in developmental performance.

Table 3: Predicting KPSP Scores through Multiple Linear Regression

Predictor Variable	β Coefficient	Standard Error	t-value	Significance	Contribution
GH Change	0.52	0.08	6.45	<0.001	42%
BMI Change	-0.38	0.06	-6.33	<0.001	15%
TSH Change	0.21	0.05	4.20	<0.001	8%
Model Summary	$R^2 = 0.65$		F = 245.6	p<0.001	65% Variance

These statistical results, the economic evaluation has shown, imply that early screening for people at high risk of diabetes, followed by a lifestyle-based program, can be economically beneficial with significant cost savings. According to benefit-cost modeling, the program will yield savings of about $1,500 per child over five years in direct medical costs. These findings were similar to those by Elashmawy et al. (2019) that blamed the cost of pharmacologic GH treatment in Egypt, when early preventive measures were absent. Thus, the improved clinical outcomes and lower costs observed in this study provide strong support for implementing systematic GH/BMI screening and treatment programs in national pediatric healthcare systems1.

The model was positioned as a Hybrid Preventive–Developmental Model based on the global frameworks as outlined by World Health Organization (WHO, 2020) and United Nations Children's Fund (UNICEF, 2023) and the operational guidelines of India's Rashtriya Bal Swasthya Karyakram (RBSK) program (Ministry of Health and Family Welfare, 2013; 2024). It brings together the preventive and community-based components of the RBSK with the principles of developmental inclusion as set out in the WHO's Improving early childhood development: WHO guideline and in the UNICEF Global report on children with developmental disabilities (UNICEF and WHO, 2023).

In contrast with the UK model centered on hospital endocrine (British Society for Pediatric Endocrinology and Diabetes (BSPED, 2023), which focuses on

pharmacological treatment and subspecialty follow-up, the present framework emphasizes early identification, behavioral changes, and non-pharmacological hormonal regulation within the school and community settings. This strategy is consistent with Olusanya et al. March 2023 in Nature Medicine, Robson et al. advocated for the prioritization of inclusive, early and flexible interventions as being key to achieving Sustainable Development Goal (SDG) 4.2 by 2030.

Additionally, the suggested model is structured in a way similar to RBSK programme, which uses a tiered school-based network to screen children for growth and developmental irregularities from 0–18 years of age (National Health Mission, 2023). Still, it builds on these templates by adding (1) biochemical validation of GH and TSH concentrations and (2) economic cost–benefit quantification—two features present in few similar frameworks. Thus, the current research model would represent scaleable, evidence-based design between preventative endocrinology and developmental public health, embodying foundational tenets of sustainability and inclusiveness which are increasingly espoused by global child-health policy leaders and stakeholders (WHO, 2021; UNICEF, 2023).

As highlighted in Table 4, comparative insights demonstrate how the current study's framework integrates international policy models (WHO/UNICEF) with national programs in practice (RBSK, BSPED), providing a unified, affordable solution for implementation in low- and middle-income (LMICs) countries.

Table 4. Comparative Frameworks of Pediatric Growth and Development Screening Models

Model / Country	Core Features	Implementation Level	Strengths	Limitations	Key References
United Kingdom (BSPED Model)	Hospital-centered endocrine care; shared-care protocols for GH therapy; focus on pharmacological management.	Specialized hospitals within NHS.	High diagnostic accuracy; clear referral structure.	Limited community screening; high treatment cost.	BSPED (2023). *GH Shared Care Guidelines for Pediatric Endocrinology*.
India (RBSK Program)	Nationwide early-childhood	Public health system through	Wide coverage; preventive	State-level variability; limited	Ministry of Health and Family

	screening (0–18 years); school and community-based detection of developmental and metabolic disorders.	National Health Mission (NHM).	orientation; free follow-up and surgery.	biochemical validation.	Welfare (2013); NHM (2023). *Operational Guidelines – RBSK.*
Saudi Arabia	Hybrid hospital–primary care system; digital e-health integration for pediatric endocrinology.	National health infrastructure.	Expanding endocrine capacity; early electronic monitoring.	Limited school-based preventive integration.	Saudi Health Council (2022); Alghamdi et al. (2023).
WHO/UNICEF Global Frameworks	*Nurturing Care Framework* and *Global Report on Developmental Disabilities* focusing on inclusion and early intervention.	International (policy level).	Universal principles for prevention and inclusivity; emphasis on SDG 4.2.	Lack of operational detail for national implementation.	WHO (2020); UNICEF (2023); Olusanya et al. (2023).
Current Study Model (Hybrid Preventive–Developmental)	Community- and school-based multi-center model integrating GH/BMI screening, behavioral counseling, and economic evaluation.	Mixed health systems (LMICs).	Combines preventive endocrinology with cost–benefit validation; scalable and sustainable.	Requires extended longitudinal validation (> 1 year).	Present study; WHO (2021); UNICEF (2023); Elashmawy et al. (2019).

In conclusion, the findings provided robust evidence for the effectiveness of the early GH and BMI screening and intervention framework. Results: At baseline (N = 1,000, age = 5.50 ± 2.87 years), participants were moderately affected, with low–

normal GH production and variable thyroid activity. Pre-intervention GH was predominantly GH20 (range 1.59 ± 0.83 ng/mL; Table 6), TSH was (2.94 ± 1.56 μIU/mL), and BMI was 23.94 ± 0.56 kg/m², overweight children.

Table 6: Study Variable Descriptive Statistics (N = 1,000)

Variable	N	Mean	Std. Deviation	95% CI Lower	95% CI Upper
Age (years)	1,000	5.50	2.87	5.32	5.68
Growth Hormone Before (ng/mL)	1,000	1.59	0.83	1.54	1.65
Growth Hormone After (ng/mL)	1,000	6.54	0.87	6.48	6.59
TSH Before (μIU/mL)	1,000	2.94	1.56	2.85	3.04
TSH After (μIU/mL)	1,000	5.04	0.32	5.02	5.06
BMI Before (kg/m²)	1,000	23.94	0.56	23.90	23.97
BMI After (kg/m²)	1,000	19.23	0.43	19.20	19.26

311% GH Increase **20%** BMI Reduction **71%** TSH Improvement **p<0.001** Statistical Significance

6. Study Limitations

Multiple critical restraints have to be taken into account while interpreting the results. With respect to the absence of a control group that receives no intervention, the capacity to substantively attribute statistically significant improvements to the intervention program as opposed to regression or natural developmental growth is greatly complicated.

With regard to study sample, it is comprised of children with suspected growth deficits, which may further limit generalizability to the rest of the pediatric population, thus, overestimating the effects of the intervention on children with no substantial growth deficits. In addition, the one-year period of intervention and follow up may be insufficient to capture the enduring effects of the attained results as well as those effects which are only exposed over time.

Differential acceptance of cultural customs, primary care, or ecological contexts though, can support the premise of effectiveness of the geographical contextual and

the cultural attributes of several study sites. However, the use of some validated culturally specific additional tools may induce measurement bias regarding the analysis of diverse populations.

The appropriate investments in health resources are considerably lower than the enormous costs that would arise from neglecting business interruption. The approach is holistic, as the gaps are filled by rigorous research. Randomized controlled trials, protracted periods of monitoring, and broader population sampling are all techniques aimed at bridging the gaps in weak systematic analysis.

7. Conclusion

This study investigated the impact of an integrated early detection and intervention framework for growth hormone disorders in children. The findings demonstrated significant improvements in hormonal regulation, body mass index, and developmental outcomes following the implementation of GH and BMI screening combined with lifestyle-based interventions.

The increase in area body mass index was 311% in conjunction with increased level of HGH, and some improvement shift s in some parameters which had upfront declined (e. g., head circumference) and some other parameters which had previously head circumference declined (e. g., arm length) and catch-up. These results were beyond what was available from pharmacological treatment alone and at a much lower cost. These results s indicates that the monitoring practices in place for the available treatment s could s modulate the population s health and reduce the burden of future health cares.

The provided information, especially regarding the correlation bar developmental milestones achievement and the maximization of growth hormone therapy, suggests useful information of the potential benefits for preschool programs targeting the adjunctive improvement of cognitive and psychosocial skills. Such wide value adds to the case for the regulation of growth deficits. It ought to be seen as a method for improving the society's future demographic assets.

Implementation of this plan entails cross-disciplinary cooperation to maximize the use of findings from health, education, and social sectors, and to equitably and sustainably provide access to screening and preventive intervention.

The extreme monetary advantage of preventative actions has given policymakers in health care reasonable justification for allocation of resources. Correcting these actions for maximized public health impact will require future research and longitudinal follow-up studies on the tailored screening and workflow processes for

different health care systems, as well as on the disaggregation of the various components and ideal timing for the most effective stratified interventions.

Future research should include long-term longitudinal studies (5–10 years) to evaluate the sustainability of post-intervention gains and identify predictors of continued improvement versus decline

Further work is needed to advance point-of-care testing technologies, mobile health solutions, and tiered community-health-worker training to strengthen early

Screening in resource-limited settings.

Integrating artificial intelligence and machine-learning models into risk estimation and personalized intervention design represents a promising direction for optimizing screening efficiency.

These findings highlight the importance of implementing systematic early screening programs within pediatric healthcare systems, particularly in low- and middle-income countries. Policymakers and healthcare providers should prioritize early detection strategies to improve child development outcomes while reducing long-term healthcare expenditures.

8. References

1. BSPED. (2023). Growth Hormone Shared Care Guidelines for Pediatric Endocrinology. British Society for Paediatric Endocrinology and Diabetes. https://www.bsped.org.uk/media/alxow2wv/gh-shared-care-guidelines-20240206.pdf

2. Abd El-Shaheed, A., Mahfouz, N. N., Elabd, M. A., and Sallam, S. F. (2020). Physical activity patterns in Egyptian obese and nonobese adolescents assessed using a validated WHO questionnaire. *Journal of the Arab Society for Medical Research, 15*(1), 6-10. https://doi.org/10.4103/jasmr.jasmr_24_19

3. Abosree, T. H., Shedeed, W. K., and Abdelaziz, N. S. (2022). Evidence-based obesity prevention program among primary school students according to 100 million health initiative. *Journal of Nursing Science - Benha University, 3*(2), 1099-1120.

4. Alatzoglou, K. S., Webb, E. A., Le Tissier, P., et al. (2014). Isolated Growth Hormone Deficiency (GHD) in Childhood and Adolescence: Recent Advances. *Endocrine Reviews, 35*, 376-432.

5. Alghamdi, A. M., Alotaibi, F., and Al-Harbi, R. (2023). Digital integration in pediatric endocrine healthcare: A Saudi model. Saudi Journal of Biological Sciences, 30(2), 124–132.

6. Alhawyan, F. S. (2021). Mortality in acromegalic patients: etiology, trends, and risk factors. *Cureus, 13*(4).

7. Almalki, M. H., Ahmad, M. M., Alqahtani, A., Almistehi, W. M., Ekhzaimy, A., Asha, M. J., and Aldahmani, K. M. (2022). Contemporary Management of Acromegaly: A Practical Approach. *Journal of Diabetes and Endocrine Practice, 5*(03), 092103.

8. Balotro, M. (2021). *Improving general developmental screening and surveillance using ASQ-3 at a pediatric primary care practice* (Doctoral project, Touro University Nevada).

9. Bamford, L., Martin, P., Slemming, W., and Richter, L. (2019). Improving the early development of children through quality health care. *South African Health Review, 2019*, 145-156.

10.Blum, W. F., Alherbish, A., Alsagheir, A., et al. (2018). The growth hormone--insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. *Endocrine Connections, 7*, R212-R222.

11.Brettell, E., Högler, W., Woolley, R., Cummins, C., Mathers, J., Oppong, R., Roy, L., Khan, A., Hunt, C., and Dattani, M. (2023). The Growth Hormone Deficiency (GHD) Reversal Trial: effect on final height of discontinuation versus continuation of growth hormone treatment in pubertal children with isolated GHD—a non-inferiority Randomised Controlled Trial (RCT). *Trials, 24*, 548. doi:10.1186/s13063-023-07562-z

12.Bruner, C., Johnson, K., Hayes, M., Bailey, M., Dworkin, P., Hild, J., and Willis, D. (2020). *Young child health transformation: What practice tells us (Working Paper).* InCK Marks Child Health Care Transformation Series.

13.Children's Safety Network. (2020). Framework for quality improvement and innovation in child safety: A guide to implementing injury and violence prevention strategies and programs. Washington, DC: HRSA.

14.Colao, A., Pivonello, C., Grasso, L. F., and Pirchio, R. (2022). Acromegaly. In *Endocrine Pathology* (pp. 9-11). Cham: Springer International Publishing.

15.Colizzi, M., Lasalvia, A., and Ruggeri, M. (2020). Prevention and early intervention in youth mental health: is it time for a multidisciplinary and trans-diagnostic model for care? *International Journal of Mental Health Systems, 14*, 23. doi:10.1186/s13033-020-00356-9

16.Cowie, J., Nicoll, A., Dimova, E. D., Campbell, P., and Duncan, E. A. (2020). The barriers and facilitators influencing the sustainability of hospital-based interventions: a systematic review. *BMC Health Services Research, 20*, 588. doi:10.1186/s12913-020-05434-9

17.Elashmawy, H., Foo, J., Dinet, J., and Paulus, M. (2019). Cost-effectiveness of Easypod™ device versus other somatotropin delivery techniques in Egypt in treatment of growth hormone deficiency. *Cost Effectiveness and Resource Allocation, 17*, 11. doi:10.1186/s12962-019-0179-3

18. Elashmawy, M., et al. (2019). Cost-effectiveness of growth hormone therapy in pediatric endocrine disorders. Journal of Pediatric Endocrinology and Metabolism, 32(5), 567–576.

19.Esposito, D., Boguszewski, C. L., Colao, A., Fleseriu, M., Gatto, F., Jørgensen, J. O. L., ... and Johannsson, G. (2024). Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management. *Nature Reviews Endocrinology, 20*(9), 541-552.

20.Ferruzzi, A. V. (2023). The influence of growth hormone on pediatric body composition: A systematic review. *Frontiers in Endocrinology, 14*, 1093691.

21.Gollins, L. A., Phillips, W., Becker, P. J., Bellini, S. G., and Wong Vega, M. (2025). Applying the Malnutrition Care Score framework to pediatric populations: Implications for enhancing health equity. *Journal of the Academy of Nutrition and Dietetics, 125*(9S), S10-S16. https://doi.org/10.1016/j.jand.2025.05.013

22.Grimberg, A. D. (2016). Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents. *Hormone Research in Paediatrics, 86*, 361-397.

23.Harrington, J. (2022). An approach to the patient with delayed puberty. *The Journal of Clinical Endocrinology and Metabolism, 107*, 1739-1750.

24.Health Service Executive. (2018). *Framework for the national healthy childhood programme.* Dublin: HSE Strategy and Planning and Primary Care Division.

25.Hijij, Z. E. H. (2022). *Socioeconomic determinants and childhood obesity in Egypt: A secondary analysis of Egypt Demographic Health Survey, 2014* (Master's thesis). Uppsala University.

26.Hoang, N.-P. T., Ma, T., Silverwood, A. J., and Sanders, M. R. (2024). Place-based approach to support children's development towards sustainable development goals: A scoping review of current effort and future agenda. *Children and Youth Services Review, 164*, 107873. https://doi.org/10.1016/j.childyouth.2024.107873

https://research.rug.nl/files/700030812/s41591-023-02291-x.pdf

27.Ibba, A., and Loche, S. (2022). Diagnosis of growth hormone deficiency without GH stimulation tests. *Frontiers in Endocrinology, 13*, 853290. https://doi.org/10.3389/fendo.2022.853290

28.Jones, B., Paterson, A., English, M., and Nagraj, S. (2023). Improving child health service interventions through a theory of change: A scoping review. *Frontiers in Pediatrics, 11*, 1037890. https://doi.org/10.3389/fped.2023.1037890

29.Loche, S. D. (2018). Growth hormone deficiency in the transition age. *Transition of Care.* Karger Publishers.

30.Lowe, B., Barzel, R., and Holt, K. (2016). *Integrating sustainable oral health services into primary care in school-based health centers: A framework.* Washington, DC: National Maternal and Child Oral Health Resource Center.

31.Malone, S., Newland, J., Kudchadkar, S. R., Prewitt, K., McKay, V., Prusaczyk, B., Proctor, E., Brownson, R. C., and Luke, D. A. (2022). Sustainability in pediatric hospitals: An exploration at the intersection of quality improvement and

implementation science. *Frontiers in Health Services, 2*, 1005802. doi:10.3389/frhs.2022.1005802

32.Melmed, S. (2019). Pathogenesis and Diagnosis of Growth Hormone Deficiency in Adults. *New England Journal of Medicine, 380*, 2551-2562.

33.Ministry for Health (Malta). (2022). *A national health systems strategy for Malta 2023-2030: Investing successfully for a healthy future.* Valletta: Government of Malta.

34. Ministry of Health and Family Welfare (Government of India). (2013). Operational Guidelines: Rashtriya Bal Swasthya Karyakram (RBSK). National Health Mission. https://nhm.gov.in/images/pdf/programmes/RBSK/Operational_Guidelines/Operational%20Guidelines_RBSK.pdf

35.Ministry of Health and Family Welfare (Government of India). (2024). Annual Report 2024–2025. Government of India. https://www.mohfw.gov.in/sites/default/files/Final%20Printed%20English%20AR%202024-25.pdf

36.Moldovan, F., Blaga, P., Moldovan, L., and Bataga, T. (2022). An innovative framework for sustainable development in healthcare: The human rights assessment. *International Journal of Environmental Research and Public Health, 19*(4), 2222. https://doi.org/10.3390/ijerph19042222

37.Mustafa, R., Jovic, A., Rangelova, V., Borisova, I., Kuttumuratova, A., and Weber, M. (2024). *Monitoring children's development through primary health care in Europe and Central Asia: Directions for policy and practice.* Geneva: UNICEF Regional Office for Europe and Central Asia and WHO Regional Office for Europe.

38.National Health Mission (NHM). (2023). Coverage and Quality of Health Screening – RBSK Final Report. Government of India. https://gipe.ac.in/wp-content/uploads/2024/03/RBSK-Final-Report.pdf

39.Ndour, D. (2019). Intrauterine growth retardation, fetal growth restriction: Impact on brain development. *EC Paediatrics, 8*, 810-819.

40.Olusanya, B. O., et al. (2023). Global leadership to optimize early childhood development for children with disabilities. Nature Medicine, 29, 2492–2504.

41.Osei Bonsu, E., and Addo, I. Y. (2022). Prevalence and correlates of overweight and obesity among under-five children in Egypt. *Frontiers in Public Health, 10*, 1067522. https://doi.org/10.3389/fpubh.2022.1067522

42.Pertiwi, M. R. (2019). Relationship between parenting style and perceived information sources with stunting among children. *International Journal of Nursing and Health Services, 2*, 273-279.

43.Read, J., and Meath, C. (2025). A conceptual framework for sustainable evidence-based design for aligning therapeutic and sustainability outcomes in healthcare facilities: a systematic literature review. *Health Environment Research and Design Journal, 18*(1), 86-107. doi:10.1177/19375867241302793

44.Richter, L. M., Daelmans, B., Lombardi, J., Heymann, J., Lopez Boo, F., Behrman, J. R., ... and Britto, P. R. (2017). Investing in the foundation of sustainable development: Pathways to scale up for early childhood development. *Lancet, 389*(10064), 103-118. https://doi.org/10.1016/S0140-6736(16)31698-1

45.Salah, N., Abd El Dayem, S. M., Fawaz, L., and Ibrahim, M. (2013). Predicting growth response among Egyptian prepubertal idiopathic isolated growth hormone deficient children. *Journal of Pediatric Endocrinology and Metabolism, 26*(3-4), 247-55. doi:10.1515/jpem-2012-0074

46. Saudi Health Council. (2022). National Strategy for Pediatric Endocrinology and Growth Disorders. Riyadh, Saudi Arabia.

47.Schiariti, V., Simeonsson, R. J., and Hall, K. (2021). Promoting developmental potential in early childhood: A global framework for health and education.

International Journal of Environmental Research and Public Health, 18(4), 2007. https://doi.org/10.3390/ijerph18042007

48.Schmied, V., Kruske, S., Barclay, L., Fowler, C., Homer, C., and Kemp, L. (2011). *National framework for universal child and family health services.* Canberra: Australian Health Ministers' Conference.

49.Solomon, A., Sripada, K., Kampo, A., Pearson, L., and UNICEF Health Section. (2021). *Healthy environments for healthy children: Global programme framework.* New York, NY: United Nations Children's Fund (UNICEF).

50.Stagi, S. T. (2023). Management of Neonatal Isolated and Combined Growth Hormone Deficiency: Current Status. *International Journal of Molecular Sciences, 24*.

51. UNICEF and WHO. (2023). Global Report on Children with Developmental Disabilities: Executive Summary. UNICEF and World Health Organization. https://www.unicef.org/media/145021/file/Executive-Summary-Global-report-on-children-with-developmental-disabilities-2023.pdf

52.Wee, E. H. (2023). Hyperinsulinemic Hypoglycemia and Growth Hormone Deficiency Secondary to 20p11 Deletion. *Case Reports in Endocrinology, 2023*, 8658540.

53.Weitzman, C., Guevara, J., Curtin, M., and Mesias, M. (2025). Promoting optimal development: screening for mental health, emotional, and behavioral problems: clinical report. *Pediatrics, 156*(3), e2025073172.

54.World Health Organization (WHO). (2020). Improving Early Childhood Development: Guideline Summary. Geneva: World Health Organization. https://cdn.who.int/media/docs/default-source/mca-documents/child/early-child-development/improving-early-childhood-development-who-guideline-summary.pdf

55. World Health Organization (WHO). (2021). Nurturing Care Framework for Early Childhood Development. Geneva: WHO.

56. World Health Organization. (2016). *Report of the Commission on Ending Childhood Obesity.* Geneva: WHO.

57. World Health Organization. (2018). *Standards for improving the quality of care for children and young adolescents in health facilities.* Geneva: WHO.

58. Wu, W., and Luo, X. (2025). Long-term efficacy and safety of growth hormone in children suffering from short stature in China (CGLS): An open-label, multicenter, prospective and retrospective, observational study. *Advances in Therapy, 42*, 2957-2969. https://doi.org/10.1007/s12325-025-03146-2

59. Yuan, J., Fu, J., Wei, H., Zhang, G., Xiao, Y., Du, H., ... and Gong, H. (2022). A randomized controlled phase 3 study on the efficacy and safety of recombinant human growth hormone in children with idiopathic short stature. *Frontiers in Endocrinology, 13*, 864908. https://doi.org/10.3389/fendo.2022.864908

STARDOM UNIVERSITY

جامعة ستاردوم

مجلة ستاردوم العلمية للدراسات الطبيعية والهندسية

- مجلة ستاردوم العلمية المحكمة للدراسات الطبيعية والهندسية -
تصدر بشكل نصف سنوي عن جامعة ستاردوم

العدد الأول - المجلد الرابع 2026م

رقم الإيداع الدولي: ISSN 3756-2980